VERPAMIL

Main information

  • Trade name:
  • VERPAMIL 200 mg prolonged-release tablet
  • Dosage:
  • 200 mg
  • Pharmaceutical form:
  • prolonged-release tablet
  • Prescription type:
  • Prescription only
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • VERPAMIL 200 mg prolonged-release tablet
    Finland
  • Language:
  • English

Therapeutic information

  • Therapeutic area:
  • Verapamil
  • Product summary:
  • Suitability for use in older adult patients Verapamili hydrochloridum Avoid using in older persons. Reduce the dose in moderate and severe renal insufficiency. Significant adverse effects include bradycardia, constipation, cardiac insufficiency and swelling. Take interactions into account, especially with digoxin and beta blockers. Avoid consuming grapefruit juice during treatment.

Status

  • Source:
  • Fimea
  • Authorization status:
  • Marketing authorization granted
  • Authorization number:
  • 9018
  • Authorization date:
  • 30-11-2007
  • Last update:
  • 26-07-2018